What's in Reprieve Cardiovascular, Inc's pipeline?

Reprieve Cardiovascular, Inc has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Reprieve Cardiovascular, Inc's portfolio?

Top competitors by shared drug class: , Salix Pharms, United Guardian.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/reprieve-cardiovascular-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Reprieve Cardiovascular, Inc — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reprieve Cardiovascular, Inc pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Diuretic	Diuretic	marketed	Calculi Dissolution Agent [EPC]		Other
furosemide infusion	furosemide infusion	marketed

Therapeutic area mix

Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Salix Pharms · 1 shared drug class
United Guardian · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Reprieve Cardiovascular, Inc:

Cite this brief

Drug Landscape (2026). Reprieve Cardiovascular, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/reprieve-cardiovascular-inc. Accessed 2026-05-17.